Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Epigenetic silencing including histone modifications and DNA methylation is an important tumorigenic mechanism. However, its role in cancer immunopathology and immunotherapy is poorly understood. Using human ovarian cancers as our model, here we show that enhancer of zeste homologue 2 (EZH2)-mediated histone H3 lysine 27 trimethylation (H3K27me3) and DNA methyltransferase 1 (DNMT1)-mediated DNA methylation repress the tumour production of T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, and subsequently determine effector T-cell trafficking to the tumour microenvironment. Treatment with epigenetic modulators removes the repression and increases effector T-cell tumour infiltration, slows down tumour progression, and improves the therapeutic efficacy of programmed death-ligand 1 (PD-L1; also known as B7-H1) checkpoint blockade and adoptive T-cell transfusion in tumour-bearing mice. Moreover, tumour EZH2 and DNMT1 are negatively associated with tumour-infiltrating CD8(+) T cells and patient outcome. Thus, epigenetic silencing of TH1-type chemokines is a novel immune-evasion mechanism of tumours. Selective epigenetic reprogramming alters the T-cell landscape in cancer and may enhance the clinical efficacy of cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“epigenetic reprogramming with shRNAs targeting DNA methyltransferase 1 (DNMT1) or pan-DNMT blockers like decitabine and guadecitabine has been shown to resemble EZH2 inhibition in its capacity to promote CXCL9 and CXCL10 secretion in various models of breast, lung, and ovarian carcinoma”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have demonstrated that mutations in genes involved in the SWI-SNF chromatin remodeling complex may sensitize human tumors to ICIs and that treatment with an epigenetic modulator can potentiate the ICI-mediated antitumor response through increased production of chemokines responsible for recruiting CD8 + T cells (104-107).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [107]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The mTOR pathway has long been recognized to play a pivotal role in integrating signals at the cellular level and promote autoimmunity and carcinogenesis18,19.”
From Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“and TH1 cytokines”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & Pepe, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,854
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Cited by
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
“Polycomb repressive complex 2 (PRC2), the demethylase JMJD3-mediated histone H3 lysine 27 trimethylation (H3K27me3), and DNA methylation repress the expression of TH1-type chemokines and subsequently restrain effector T cell trafficking into the cancer microenvironment (94, 95).”
BackgroundInfluentialSelf-citationThe immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
Self-citationBagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383
“Restoration of Th1 cytokine production and enhanced responsiveness to checkpoint blockade has been demonstrated following treatment with DNMT or EZH2 inhibitors (Peng et al, 2015).”
BackgroundPitt, J. M., Marabelle, A., Eggermont, A., Soria, J.-C., Kroemer, G., & Zitvogel, L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw168 · Cited by 1,338
Thommen, D. S., & Schumacher, T. N. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.012 · Cited by 1,299
“Such sculpting can either involve repression of T cell recruitment to the tumor site (Nagarsheth et al., 2017; Peng et al., 2015) or inhibition of the functionality of T cells at that site.”
BackgroundImmune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.001 · Cited by 1,192
Targeting the cancer epigenome for therapy
Jones, P. A., Issa, J.-P. J., & Baylin, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,128
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
“DNMTi and Histone-lysine N-methyltransferase EZH2 inhibitors have also been shown to reverse epigenetic silencing of Th1-type chemokines in tumor cells, which is negatively associated with CD8 T cells in tumors and patient outcome (48).”
BackgroundDetection of immunogenic cell death and its relevance for cancer therapy
Fucikova, J., Kepp, O., Kasikova, L., Petroni, G., Yamazaki, T., Liu, P., Zhao, L., Spisek, R., Kroemer, G., & Galluzzi, L. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03221-2 · Cited by 1,138
Self-citationThe Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,080
“Recent studies suggest that exhausted T cells represent a distinct lineage of lymphocytes that is different at the transcriptional and epigenetic levels from TCM and TEM subsets of memory T cells (Peng et al., 2015; Roychoudhuri et al., 2016).”
BackgroundLang, X., Green, M. D., Wang, W., Yu, J., Choi, J. E., Jiang, L., Liao, P., Zhou, J., Zhang, Q., Dow, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0338 · Cited by 1,047
Self-citationPitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,041
“Indeed, treatment with epigenetic modulators has been shown to remove the repression over these Th1-cell-type chemokines and increase TILs and thus result in enhanced therapeutic efficacy of PD-L1 checkpoint blockade (Peng et al., 2015).”
CD8+ T cell differentiation and dysfunction in cancer
Philip, M., & Schietinger, A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00574-3 · Cited by 1,052
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
Yu, J., Green, M. D., Li, S., Sun, Y., Journey, S. N., Choi, J. E., Rizvi, S. M., Qin, A., Waninger, J. J., Lang, X., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-1131-x · Cited by 1,001
Self-citationZeng, D., Li, M., Zhou, R., Zhang, J., Sun, H., Shi, M., Bin, J., Liao, Y., Rao, J., & Liao, W. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0436 · Cited by 986
“Gene cluster A was associated with high expression of TGF-β/EMT pathway-relevant mRNAs, whereas expression of Th1/cytotoxic T lymphocyte (CTL)-related mRNAs (49) (particularly CXCL10, CXCL9, IFNG, and GZMB) was relatively low (Fig.”
BackgroundEZH2: a novel target for cancer treatment
Duan, R., Du, W., & Guo, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00937-8 · Cited by 926
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.17 · Cited by 953
CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4
Liao, P., Wang, W., Wang, W., Kryczek, I., Li, X., Bian, Y., Sell, A., Wei, S., Grove, S., Johnson, J. K., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.02.003 · Cited by 912
“Tumor volume was calculated as previously described (Peng et al., 2015).”
MethodSelf-citationTurning Cold into Hot: Firing up the Tumor Microenvironment
Duan, Q., Zhang, H., Zheng, J., & Zhang, L. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.022 · Cited by 934
Breast Cancer Immunotherapy: Facts and Hopes
Emens, L. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3001 · Cited by 863
“Studies have shown epigenetic modulation can promote an type I interferon response and restore production of T helper type 1 cytokines and chemokines (68-69).”
BackgroundQian, X., Zheng, Y., & Chen, Y. (2016) · Advanced Materials · doi:10.1002/adma.201602012 · Cited by 882
Dangaj, D., Bruand, M., Grimm, A. J., Ronet, C., Barras, D., Duttagupta, P. A., Lanitis, E., Duraiswamy, J., Tanyi, J. L., Benencia, F., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.004 · Cited by 875
“Similarly, CXCL9 expression in sorted tumor cells was minimal, and CXCL10 was low even when tumor cells were stimulated with high-dose IFNγ (40 ng/ml, Figure 4A, 4B), in line with silencing of these chemokines in ovarian cancer cells (Peng et al., 2015).”
BackgroundInfluentialChemokines and the immune response to cancer
Ozga, A. J., Chow, M. T., & Luster, A. D. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.012 · Cited by 830
Turning cold tumors into hot tumors by improving T-cell infiltration
Liu, Y.-T., & Sun, Z.-J. (2021) · Theranostics · doi:10.7150/thno.58390 · Cited by 827
House, I. G., Savas, P., Lai, J., Chen, A. X. Y., Oliver, A. J., Teo, Z. L., Todd, K. L., Henderson, M. A., Giuffrida, L., Petley, E. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1868 · Cited by 790
“Similarly, the localized application of a COX-2 inhibitor was shown to enhance therapeutic responses to anti-PD-1, associated with an increase in expression of CXCL9 and CXCL10 (63) and epigenetic modulators (EZH2i and DNMT1i) were shown to enhance antitumor immune responses associated with increased expression of CXC…”
BackgroundCold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770
“The digested NFATc3 and His-GB1 were separated and further purified using size exclusion chromatography (GE Healthcare Life Sciences “Superdex 75 10/300 GL”).”
BackgroundInfluentialThe future of cancer immunotherapy: microenvironment-targeting combinations
Murciano-Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 749
Brain immunology and immunotherapy in brain tumours
Sampson, J. H., Gunn, M. D., Fecci, P. E., & Ashley, D. M. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0224-7 · Cited by 722
Li, J., Byrne, K. T., Yan, F., Yamazoe, T., Chen, Z., Baslan, T., Richman, L. P., Lin, J. H., Sun, Y. H., Rech, A. J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.006 · Cited by 750
Self-citationMaj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733
Self-citationChow, M. T., Ozga, A. J., Servis, R. L., Frederick, D. T., Lo, J. A., Fisher, D. E., Freeman, G. J., Boland, G. M., & Luster, A. D. (2019) · Immunity · doi:10.1016/j.immuni.2019.04.010 · Cited by 716
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 702
Impact of oncogenic pathways on evasion of antitumour immune responses
Spranger, S., & Gajewski, T. F. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.117 · Cited by 665
Burr, M. L., Sparbier, C. E., Chan, K. L., Chan, Y.-C., Kersbergen, A., Lam, E. Y. N., Azidis-Yates, E., Vassiliadis, D., Bell, C. C., Gilan, O., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.008 · Cited by 649
“Consistent with the notion that PRC2 inhibition can potentiate the transcriptional response to IFN-g (Zingg et al., 2017; Peng et al., 2015; Abou El et al., 2015), genetic disruption of PRC2 dramatically augmented IFN-g-induced MHC-I expression (Figure S3A).”
BackgroundTargeting the epigenetic regulation of antitumour immunity
Hogg, S. J., Beavis, P. A., Dawson, M. A., & Johnstone, R. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0077-5 · Cited by 630
Fares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P., & Hu-Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 653
Morschhauser, F., Tilly, H., Chaidos, A., McKay, P., Phillips, T., Assouline, S., Batlevi, C. L., Campbell, P., Ribrag, V., Damaj, G. L., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30441-1 · Cited by 604
Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 607
“In ovarian cancer, silencing of CXCL9 and CXCL10 expression in tumor cells via an epigenetic mechanism inhibited T-cell infiltration.(73) Furthermore, further evidence of the involvement of proinflammatory chemokines in the inhibition of T-cell infiltration was provided by the observation that intratumoral reactive ni…”
BackgroundThe hallmarks of cancer immune evasion
Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 565
Interferon-γ: teammate or opponent in the tumour microenvironment?
Gocher, A. M., Workman, C. J., & Vignali, D. A. A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00566-3 · Cited by 582
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
Lin, H., Wei, S., Hurt, E. M., Green, M. D., Zhao, L., Vatan, L., Szeliga, W., Herbst, R., Harms, P. W., Fecher, L. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96113 · Cited by 584
Self-citationCombination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Patel, S. A., & Minn, A. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.007 · Cited by 573
“Recent studies have examined the notion that mesenchymal or stem cell-like properties gained by tumor cells may suppress their expression of TH1-type cytokines (Peng et al., 2015).”
BackgroundOng, L.-T., Lee, W. C., Ma, S., Oguz, G., Niu, Z., Bao, Y., Yusuf, M., Lee, P. L., Goh, J. Y., Wang, P., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2201376119 · Cited by 572
Self-citationRegulatory circuits of T cell function in cancer
Speiser, D. E., Ho, P.-C., & Verdeil, G. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.80 · Cited by 566
Tumor Immunology and Tumor Evolution: Intertwined Histories
Galon, J., & Bruni, D. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.018 · Cited by 540
Improving immune–vascular crosstalk for cancer immunotherapy
Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563
Shen, J., Ju, Z., Zhao, W., Wang, L., Peng, Y., Ge, Z., Nagel, Z. D., Zou, J., Wang, C., Kapoor, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0012-z · Cited by 562
Epigenetic therapy in immune-oncology
Jones, P. A., Ohtani, H., Chakravarthy, A., & De Carvalho, D. D. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0109-9 · Cited by 550
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 535
“Additionally, epigenetic modulators targeting EZH2-mediated H3K27me3 enhances the efficacy of anti-PD-1 therapy [180].”
BackgroundThe roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
Ai, L., Xu, A., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_3 · Cited by 526
Application of PD-1 Blockade in Cancer Immunotherapy
Wu, X., Gu, Z., Chen, Y., Chen, B., Chen, W., Weng, L., & Liu, X. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.006 · Cited by 531
“In contrast, noninflamed tumors with “cold” TME generally express cytokines that are associated with immune suppression or tolerance, such as IL-10, IL-35, IL-4, TGF-β et al. [111–114].”
BackgroundInfluentialTurning cold tumors hot: from molecular mechanisms to clinical applications
Zhang, J., Huang, D., Saw, P. E., & Song, E. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.04.010 · Cited by 534
Harnessing the plasticity of CD4+ T cells to treat immune-mediated disease
DuPage, M., & Bluestone, J. A. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.18 · Cited by 513
Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
Lu, Y., Chan, Y.-T., Tan, H.-Y., Li, S., Wang, N., & Feng, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01197-3 · Cited by 499
“However, with the addition of ZEB administration, the demethylation effect could be maintained [84].”
BackgroundFacilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Tang, H., Wang, Y., Chlewicki, L. K., Zhang, Y., Guo, J., Liang, W., Wang, J., Wang, X., & Fu, Y.-X. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.004 · Cited by 472
“Recently, consistent with our observations, two exceptional studies have shown that both mouse and human tumor cells can be programmed to suppress chemokine production that can limit immune infiltrates, leading to resistance to PD-1 blockade therapies (Peng et al., 2015; Spranger et al., 2015).”
Immune Checkpoint Inhibitors: Basics and Challenges
Li, B., Chan, H. L., & Chen, P. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170804143706 · Cited by 480
Kurebayashi, Y., Ojima, H., Tsujikawa, H., Kubota, N., Maehara, J., Abe, Y., Kitago, M., Shinoda, M., Kitagawa, Y., & Sakamoto, M. (2018) · Hepatology · doi:10.1002/hep.29904 · Cited by 454
“CXCL9 and CXCL10 expressions are associated with lymphocytic infiltration in many tumors.((16,30)) We found that the Immune-high subtype is characterized by a CXCL9/CXCL10-rich Th1/CTL-type cytokine/cytokine milieu, which is similar to “Immune class” as defined by the gene-expression–based approach.”
BackgroundCombining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G., & Postel-Vinay, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0267-4 · Cited by 445
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
Gide, T. N., Wilmott, J. S., Scolyer, R. A., & Long, G. V. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2267 · Cited by 454
Is autoimmunity the Achilles' heel of cancer immunotherapy?
June, C. H., Warshauer, J. T., & Bluestone, J. A. (2017) · Nature Medicine · doi:10.1038/nm.4321 · Cited by 445
Gan, L., Yang, Y., Li, Q., Feng, Y., Liu, T., & Guo, W. (2018) · Biomarker Research · doi:10.1186/s40364-018-0122-2 · Cited by 426
“Treatment with epigenetic modulators increases tumor infiltration of effector T cell, slows down tumor progression, and improves the therapeutic efficacy of PD-L1 checkpoint blockade and adoptive T-cell transfusion in tumor-bearing mice [38].”
BackgroundThe emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433
Oncolytic viruses as engineering platforms for combination immunotherapy
Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 417
Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
Lei, Q., Wang, D., Sun, K., Wang, L., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00672 · Cited by 421
“Epigenetic modulation involves in silencing Th1 type chemokines such as CXCL9 and CXCL10, and thereby impeding anti-PD1/PDL1 efficacy by mediating T cell trafficking to the tumor site (Peng et al., 2015).”
BackgroundInfluentialEffector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
Wang, W., Kryczek, I., Dostál, L., Lin, H., Tan, L., Zhao, L., Lu, F., Wei, S., Maj, T., Peng, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.009 · Cited by 422
Self-citationThe language of chromatin modification in human cancers
Zhao, S., Allis, C. D., & Wang, G. G. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00357-x · Cited by 402
Zhu, Y., Yang, J., Xu, D., Gao, X.-M., Zhang, Z., Hsu, J. L., Li, C.-W., Lim, S.-O., Sheng, Y.-Y., Zhang, Y., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318419 · Cited by 419
Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy
Li, A., Yi, M., Qin, S., Song, Y., Chu, Q., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0721-x · Cited by 413
CD4 T Helper Cell Subsets and Related Human Immunological Disorders
Zhu, X., & Zhu, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218011 · Cited by 373
“Interestingly, the epigenetic silencing of Th1-type chemokines has been reported as a novel immune-evasion mechanism of tumors [65]; this indicates that a selective epigenetic reprogramming may enhance the clinical efficacy of cancer therapy.”
BackgroundImmune checkpoint therapy in liver cancer
Xu, F., Jin, T., Zhu, Y., & Dai, C. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0777-4 · Cited by 397
“3-Deazaneplanocin A and 5-aza-2′deoxycytidine, two important DNMTi, enhanced the therapeutic efficacy of PD-L1 blockade in reducing tumor volume, increasing tumor infiltrating CD8+ T cells and Th1-type chemokine expression in ovarian cancer in C57/BL6 mice [72].”
BackgroundLessons learned from the blockade of immune checkpoints in cancer immunotherapy
Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 381
“In fact, EOCs developing in germline BRCA mutation carriers (gBRCAm, “BRCAness” phenotype) are characterized by a higher mutational load and greater number of neo-antigens that enhance the recruitment of TILs.”
BackgroundInfluentialChemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy
Vilgelm, A. E., & Richmond, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00333 · Cited by 379
“For instance, treatment of ovarian cancer cells with epigenetic modifiers reversed the EZH2 and DNMT1 suppression of expression of the CXCR3 ligands, CXCL9, and CXCL10, resulting in T cell influx into the tumor and improved response to T cell transfer and anti-PD-L1 blockade therapy (160).”
BackgroundMechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
“Alternatively, tumors such as ovarian can use epigenetic mechan- isms to silence the T-cell attracting chemokines CXCL9 and CXCL10 [97].”
BackgroundInfluentialTumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance
Liu, Y., Liang, G., Xu, H., Dong, W., Dong, Z., Qiu, Z., Zhang, Z., Li, F., Huang, Y., Li, Y., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.04.001 · Cited by 361
Cancer Epigenetics, Tumor Immunity, and Immunotherapy
Cao, J., & Yan, Q. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.003 · Cited by 346
“Counterintuitively, KDM6B (JMJD3), the methyltransferase with the counter role of KMT6A (EZH2), also suppresses chemokine expression [32].”
BackgroundXiao, X., Lao, X.-M., Chen, M.-M., Liu, R.-X., Wei, Y., Ouyang, F.-Z., Chen, D.-P., Zhao, X.-Y., Zhao, Q., Li, X.-F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1408 · Cited by 352
Self-citationDevelopment of Immunotherapy Combination Strategies in Cancer
Yap, T. A., Parkes, E. E., Peng, W., Moyers, J. T., Curran, M. A., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1209 · Cited by 330
Zheng, H., Zhao, W., Yan, C., Watson, C. C., Massengill, M., Xie, M., Massengill, C., Noyes, D. R., Martinez, G. V., Afzal, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2584 · Cited by 340
“An additional HDACi in the Oncology Drugs Set, vorinostat, on the other hand increased Cxcl9 and Cxcl10 expression more strongly than Ccl5 expression (Supplementary Fig.”
BackgroundInfluentialEpigenetic drivers of tumourigenesis and cancer metastasis
Chatterjee, A., Rodger, E. J., & Eccles, M. R. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.004 · Cited by 328
DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats
Brocks, D., Schmidt, C. R., Daskalakis, M., Jang, H. S., Shah, N. M., Li, D., Li, J., Zhang, B., Hou, Y., Laudato, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3889 · Cited by 339
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
Zingg, D., Arenas-Ramirez, N., Sahin, D., Rosalia, R. A., Antunes, A. T., Haeusel, J., Sommer, L., & Boyman, O. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.007 · Cited by 330
Si, W., Liang, H., Bugno, J., Xu, Q., Ding, X., Yang, K., Fu, Y., Weichselbaum, R. R., Zhao, X., & Wang, L. (2022) · Gut · doi:10.1136/gutjnl-2020-323426 · Cited by 321
Gong, Z., & Dai, Z. (2021) · Advanced Science · doi:10.1002/advs.202002178 · Cited by 320
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
Cañadas, I., Thummalapalli, R., Kim, J. W., Kitajima, S., Jenkins, R. W., Christensen, C. L., Campisi, M., Kuang, Y., Zhang, Y., Gjini, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0116-5 · Cited by 312
Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity
Wang, D., Quiros, J., Mahuron, K., Pai, C.-C., Ranzani, V., Young, A., Silveria, S., Harwin, T., Abnousian, A., Pagani, M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.050 · Cited by 318
“Moreover, EZH2 has been shown to regulate chemokine production within cancer cells, shaping their immune microenvironment and making it more permissive to cancer progression (Nagarsheth et al., 2016; Peng et al., 2015).”
Ennishi, D., Takata, K., Béguelin, W., Duns, G., Mottok, A., Farinha, P., Bashashati, A., Saberi, S., Boyle, M., Meissner, B., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1090 · Cited by 318
“A recent study has also demonstrated that EZH2 and DNMT1 gene expression was negatively correlated with the amount of TILs through silencing of Th1-type chemokines (44).”
BackgroundHow chemokines organize the tumour microenvironment
Mempel, T. R., Lill, J. K., & Altenburger, L. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-023-00635-w · Cited by 281
“An alternative, epigenetic mechanism to limit type I immunity has been observed in human ovarian cancer cells, in which both enhancer of zeste 2 (EZH2)-mediated histone H3K27 trimethylation and DNA methyltransferase 1 (DNMT1)-mediated DNA methylation directly repress CXCL9 and CXCL10 genes 204 .”
Migrating into the tumor: a roadmap for T cells
van der Woude, L. L., Gorris, M. A. J., Halilovic, A., Figdor, C. G., & de Vries, I. J. M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.09.006 · Cited by 307
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Chabanon, R. M., Rouanne, M., Lord, C. J., Soria, J.-C., Pasero, P., & Postel-Vinay, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00386-6 · Cited by 293
Spranger, S. (2016) · International Immunology · doi:10.1093/intimm/dxw014 · Cited by 290
Stone, M. L., Chiappinelli, K. B., Li, H., Murphy, L. M., Travers, M. E., Topper, M. J., Mathios, D., Lim, M., Shih, I.-M., Wang, T.-L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712514114 · Cited by 290
“Similarly, another study showed that epigenetic therapy induced tumor expression of CXCL10, which led to an increase in T effector cells in the tumor microenvironment and to an improved response to α-PD-L1 therapy (15).”
BackgroundResult
Metadata
- Authors
- Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., Kotarski, J., Tarkowski, R., Dou, Y., Cho, K., Hensley-Alford, S., Munkarah, A., Liu, R., & Zou, W.
- Affiliations
- University of Michigan (US)
- Medical University of Lublin (PL)
- Henry Ford Health (US)
- Corresponding author
- Zou, Weiping
- ORCID
- Venue
- Nature
- Published
- 2015-10-26
- Volume
- 527
- Issue
- 7577
- Pages
- 249-253
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4779053
- OpenAlex
- W2103021272
- Cited by
- 1,201
- References
- 37
- Citations by year
- 2026: 79 · 2025: 100 · 2024: 104 · 2023: 132 · 2022: 155 · 2021: 159 · 2020: 125 · 2019: 109 · 2018: 85 · 2017: 89 · 2016: 61 · 2015: 2
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (CA099985, R01CA123088, R01CA152470, CA193136, R01CA156685, CA123088, 5P30 CA 46592, CA156685, CA152470, R01CA171306, R01CA193136, CA171306, R01CA099985, F31CA189440, R01CA190176, CA190176, P30CA046592)
- National Institute of General Medical Sciences (R01GM082856)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- epigenetic silencing, EZH2, DNMT1, CXCL9, CXCL10, ovarian cancer, tumor immunosuppression, adoptive T cell therapy, CD8+ T cells, H3K27me3, DNA methylation, histone modifications, tumor microenvironment, immunotherapy response
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, DNA (Cytosine-5-)-Methyltransferase 1, Animals, DNA (Cytosine-5-)-Methyltransferases, Female, Histones, Humans, Immunotherapy, Lysine, Ovarian Neoplasms, Prognosis, Tumor Cells, Cultured, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Th1 Cells, Chemokines, Tumor Escape, DNA Methylation, Gene Silencing, Xenograft Model Antitumor Assays, Epigenesis, Genetic, Mice, Chemokine CXCL10, Chemokine CXCL9, B7-H1 Antigen, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.